Table 2.
Primary clinical outcomes
| Patients N = 33 | Differences A vs. Pa | Patients with Amantadine(A) N = 16 | Patients with Placebo (P) N = 17 |
|---|---|---|---|
| Response | 13 | 6 | |
| Non-response | 3 | 11 | |
| Response rate (%) | 13/16 = 0.8125 (81.25%) | 6/17 = 0.3529 (35.29%) | |
| Statistical significance (defined as p < 0.05) | p = 0.003 | ||
| Absolute response difference | 81.25–35.29 = 45.96% | ||
| Relative response (RR) | 81.25/35.29 = 2.302 | ||
| Odds | 13/3 = 4.33 | 6/11 = 0.55 | |
| Odds ratio (OR) | 4.33/0.55 = 7.872 | ||
| Effect size of difference (expressed as Cohen’s d) | d = 1.0461 | ||
| Effect size of difference (expressed as Hedges’s g) | g = 1.0175 | ||
| Effect size of association (correlation coefficient r) | r = 0.463 |
aPrimary outcome defined as changes between pre-treatment scores and scores at week 7 of the HAMD (DHAMD). Clinical endpoint defined as reduction of HAMD ≥25%. Time endpoint: 7 weeks